

BLAU FARMACÊUTICA S.A.

Publicly Held Corporation

NIRE 35.300.416.406

CVM Code 2462-7

MATERIAL FACT

**Blau entered into a partnership with JSR Life Sciences Group
to develop highly complex biotechnological drugs**

BLAU FARMACÊUTICA S.A. (B3: BLAU3; “Blau” or “Company”), company operating in the biotechnology industry, in compliance with CVM resolution no. 44 of August 23, 2021, as amended, hereby informs its shareholders and the market in general that, on October 18th, signed a long-term agreement with Similis Bio, a company owned by JSR Life Sciences (Tokio Stock Exchange: JSCPY), for tech transfer and development of four biosimilar products indicated for oncology, inflammations in general and hematology (“Agreement”).

Similis Bio will provide technology transfer to Blau, including cell lines, analytical data, methodologies and upstream and downstream processes. Blau will produce the medicines locally in its industrial facility of Biotechnological APIs (Active Pharmaceutical Ingredients), in Cotia, and has no territorial commercial restriction. The Company's intention is to sell the products in America by itself, through its subsidiaries, and make partnership with local organizations in other regions.

The Company estimates that total investment in the project could exceed USD 100 million over the next 10 years including, without limitation, internal R&D expenses, investment in production lines and payments to be made by Blau to Similis Bio under the agreement for licensing, development services and long-term royalties. This estimate is conditional on the achievement of operational and commercial goals, as well as the sales curve of the drugs produced by Blau with the technology provided by Similis Bio.

This long-term partnership will begin with the development of four state-of-art monoclonal antibodies – which, according to IQVIA, are among the molecules with the largest addressable market in the world and, combined, have a currently TAM (Total Addressable Market) of more than USD 42 billion, being BRL 4 billion in the Brazil – so Blau can benefit from a robust market for these products in the next decade. The partnership can be extended to the development of new products.

The launch of these drugs will be a milestone in the history of Blau and Brazil, which will have a national manufacturer developing and producing locally APIs (Active Pharmaceutical Ingredients) and biosimilar medicines.

This initiative will give the world population greater access to advanced medicines and reinforces Blau's position in becoming a reference in the production of biosimilars in Latin America.

The Company continues to invest in the development of new APIs and new high complexity drugs, in addition to continuing to expand its production capacity, geographic presence and relevance in the health sector.

Cotia, October 25, 2022.

Douglas Leandro Rodrigues
CFO and Investor Relations Officer

About Blau Farmacêutica:

Blau (BLAU3) is a leading Pharmaceutical Industry in Brazil in the institutional segment and a pioneer in biotechnology, with a portfolio of private brands of highly complex medicines focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, specialties, antibiotics, acting in several therapeutic classes.

Blau has a continental presence, currently in 7 Latin American countries and the United States, and has a state-of-the-art pharmaceutical industrial complex, consisting of five industrial plants, with cutting-edge technology, dedicated to the production of biological, oncological, antibiotics, injectable anesthetics and biotechnology.